基于STAT3的双重抑制剂用于癌症治疗的研究进展
Xiaojuan Yang1, Lu Xu1, Li Yang1
1School of Pharmacy, Xinxiang University, Xinxiang 453003, China.
Bioorganic & medicinal chemistry
|June 27, 2023
概括
向信号转换器和转录3激活器 (STAT3) 对于癌症治疗至关重要. 本综述探讨了将STAT3抑制与其他抗癌策略相结合的双抑制剂,以克服治疗挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 信号转换器和转录3激活器 (STAT3) 是一个关键的转录因子,调节细胞存活,细胞循环和免疫反应.
- STAT3涉及癌症进展和恶性瘤等级,使其成为一个有前途的治疗点.
- 目前的STAT3抑制剂面临的挑战包括毒性,有效性有限和耐药性.
研究的目的:
- 审查开发涉及STAT3.3的双抑制剂的理论基础.
- 要总结这些新型抑制剂的结构-活性关系 (SARs).
- 探索克服STAT3单一治疗局限性的策略.
主要方法:
- 关于STAT3抑制剂和双目标策略的文献综述.
- 对癌症中STAT3信号通路的现有研究进行分析.
- 对组合抑制剂的结构-活性关系的检查.
主要成果:
- STAT3 抑制剂与 IDO1i,HDACi 和 NF-κB 抑制剂等其他抗癌剂具有协同作用.
- 双位抑制剂为克服单一治疗缺点提供了一个潜在的替代方案.
- 了解SAR对于设计有效的双目标化合物至关重要.
结论:
- 基于STAT3的双抑制剂代表了癌症治疗的有前途的治疗途径.
- 涉及STAT3抑制的组合疗法可以增强抗瘤活性并克服抗药性.
- 对SAR的进一步研究将指导下一代癌症疗法的发展.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K


